Cytomegalovirus immune globulin intravenous (human) - Biologic Drug Details

Summary for cytomegalovirus immune globulin intravenous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for cytomegalovirus immune globulin intravenous (human)

Recent Clinical Trials for cytomegalovirus immune globulin intravenous (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Fernanda P Silveira, MD, MS	PHASE4
Kamada, Ltd.	PHASE4
Novartis	Phase 2

See all cytomegalovirus immune globulin intravenous (human) clinical trials

Pharmacology for cytomegalovirus immune globulin intravenous (human)

Mechanism of Action	Virus Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for cytomegalovirus immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for cytomegalovirus immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for cytomegalovirus immune globulin intravenous (human) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Cytomegalovirus Immune Globulin Intravenous (Human)

Last updated: July 30, 2025

Introduction

Cytomegalovirus (CMV) immune globulin intravenous (human) (CMV IGIV) represents a specialized biologic therapy used primarily to prevent and treat CMV infections, especially in immunocompromised populations such as transplant recipients and hematologic malignancy patients. The biological complexity of CMV IGIV, combined with expanding patient populations and evolving clinical guidelines, influences its market dynamics and financial prospects. This comprehensive analysis explores the drivers shaping this landscape, future growth trajectories, and strategic considerations for stakeholders.

Overview of CMV and Role of CMV IGIV

CMV, a member of the Herpesviridae family, infects a significant proportion of the global population—approximately 60-80%—with lifelong latent infection in most cases. While generally asymptomatic in immunocompetent individuals, CMV poses substantial health risks in immunosuppressed patients, such as organ transplant recipients, bone marrow transplant patients, and those with hematologic malignancies. CMV infections can lead to severe complications, including organ rejection, pneumonia, gastrointestinal disease, and retinitis, underscoring the importance of effective prophylactic and therapeutic measures.

CMV IGIV is derived from pooled human plasma and contains high titers of anti-CMV immunoglobulins. It functions by providing passive immunity, neutralizing CMV, and reducing disease severity. Its administration, in conjunction with antiviral agents, forms a key component in CMV management protocols, although its utilization varies based on patient risk profiles, clinical guidelines, and health system capacities.

Market Drivers

1. Rising Incidence of Transplantation

The expanding global organ transplantation programs have significantly increased the population at risk for CMV infections. The demand for prophylactic therapies, including CMV IGIV, correlates positively with transplantation rates. According to the International Society for Heart and Lung Transplantation, over 40,000 solid organ transplants are performed annually worldwide, each requiring CMV management strategies [1].

2. Growing Immunosuppressed Populations

Advances in oncology, chemotherapy, and immunosuppressive therapies have broadened the pool of immunocompromised patients susceptible to CMV. Hematopoietic stem cell transplantation (HSCT) and solid organ transplantation patients often require CMV prophylaxis and preemptive therapy, reinforcing the need for biologic agents like CMV IGIV.

3. Elevated Clinical Awareness and Guidelines

Enhanced understanding of CMV's morbidity and mortality has prompted updates to clinical guidelines by organizations such as the American Society of Transplantation (AST) and the Infectious Diseases Society of America (IDSA). These guidelines increasingly recommend CMV-specific immunoglobulin therapies in high-risk populations, boosting market demand.

4. Limited Competition and Regulatory Approvals

Currently, few branded or biosimilar options for CMV IGIV exist, providing a near-monopoly status for established manufacturers. This exclusivity sustains pricing power and profitability.

5. Emerging Therapeutic Combinations and Personalized Approaches

Combining CMV IGIV with antiviral agents like ganciclovir and valganciclovir enhances efficacy. The move toward personalized prophylaxis regimens, integrating immune globulins, enhances therapeutic outcomes, thereby increasing demand for CMV IGIV.

Market Challenges and Constraints

1. High Cost and Reimbursement Complexity

The high production costs associated with plasma-derived biologics translate into elevated treatment costs. Reimbursement policies vary globally, often limiting access in low-to-middle-income regions, constraining market expansion.

2. Limited Phase III Efficacy Data and Regulatory Hurdles

Despite widespread clinical use, comprehensive randomized controlled trials (RCTs) demonstrating definitive benefits remain sparse, leading to inconsistent uptake and regulatory scrutiny.

3. Availability and Supply Limitations

Plasma-derivation processes depend on plasma donor pools, which are vulnerable to donor shortages, emerging infectious disease outbreaks, and stringent regulatory constraints affecting plasma collection and fractionation.

4. Competition from Antiviral Agents and Novel Therapies

The development of potent antiviral drugs, such as letermovir, with targeted mechanisms, presents alternative prophylactic options, potentially reducing reliance on immunoglobulins.

Financial Trajectory and Market Forecast

Current Market Size and Revenue Potential

The global CMV immune globulin market was valued at approximately USD 200-250 million in 2022, with projected compound annual growth rates (CAGR) of 4-6% over the next five years. Growth is driven predominantly by increased transplant activity and evolving clinical practices.

Regional Market Dynamics

North America commands the largest market share, owing to high transplantation rates, advanced healthcare infrastructure, and favorable reimbursement policies. Europe follows closely, supported by mature transplant programs and regulatory acceptances. Emerging markets in Asia-Pacific and Latin America exhibit rising demand due to expanding healthcare access and transplant activities, though price sensitivity and infrastructural challenges temper growth.

Innovation and Pipeline Development

While plasma-derived CMV IGIV remains the standard, biotech companies are exploring monoclonal antibodies, recombinant immunoglobulins, and novel antiviral combinations. These innovations may eventually disrupt incumbents, influencing long-term revenue streams.

Strategic Opportunities and Risks

Investors should monitor potential biosimilar entrants, regulatory modifications affecting plasma-based therapies, and the impact of newer antiviral agents. Strategic acquisitions of plasma collection centers and R&D investments in alternative biologics could prove pivotal.

Conclusion

The market for CMV immune globulin intravenous (human) is characterized by steady growth driven by rising transplantation and immunosuppressed populations, reinforced by updated clinical guidelines emphasizing prophylaxis. Despite challenges related to cost, regulatory hurdles, and emerging therapies, the segment benefits from limited competition and high clinical demand. Continued innovation, strategic supply chain management, and broader access expansion can enhance financial trajectories in this niche but vital biologic space.

---

Key Takeaways

• The CMV IGIV market is projected to grow 4-6% CAGR over the next five years, driven by rising transplant procedures and immunosuppressed populations globally.
• Market drivers include increased clinical awareness, evolving guidelines, and limited therapeutic alternatives.
• Challenges encompass high costs, plasma supply limitations, and competition from new antiviral therapies.
• Regional dynamics favor North America and Europe, with emerging opportunities in Asia-Pacific and Latin America.
• Innovation in biologic and antiviral options may reshape the competitive landscape, emphasizing the need for strategic R&D investments.

---

FAQs

Q1: What is the primary patient population benefiting from CMV IGIV?
Immunocompromised patients, especially solid organ and hematopoietic stem cell transplant recipients, are the main beneficiaries, due to their high risk for CMV disease.

Q2: How does CMV IGIV compare with antiviral drugs in prophylaxis?
While antiviral agents are frontline prophylactics, CMV IGIV provides passive immunity and is used adjunctively or in high-risk cases, especially when antiviral resistance or toxicity is a concern.

Q3: What are the main regulatory challenges facing CMV IGIV manufacturers?
Regulatory agencies demand robust efficacy and safety data, quality control of plasma products, and compliance with plasma collection and processing standards, which can be complex and costly.

Q4: Are biosimilars likely for CMV IGIV in the near future?
Given the current plasma-derived nature and high complexity, biosimilar development is challenging and not imminent; however, emerging biologics and recombinant alternatives may influence future competition.

Q5: How do supply chain disruptions impact the market?
Plasma shortages, caused by regulatory restrictions, donor availability, or pandemics, can constrain production, elevate costs, and impact market availability and pricing.

---

References

[1] International Society for Heart and Lung Transplantation. Transplant Registry Reports, 2022.